Evidence map›Paper›PMID 41071290›Full record

ArticleAnnals of hematology2025

A comprehensive analysis of B symptoms reveals prognosis and heterogeneity across different sites of diffuse large B-cell lymphoma.

Chaoling Wu, Yongjun Zhang, Fan Yang, Jinyuan Xiao, Chao Chen, Min Li, Changjian Yan, Xiaoni Liu, Xiaoyu Hao, Yuqi Zhang and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Chaoling Wu *Department of Respiratory Medicine, Affiliated Hospital of Jiujiang University, Jiujiang, 332000, China.
Yongjun Zhang *Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Fan Yang *Institute of Medical Information Engineering, Gannan Medical University, Ganzhou, 341000, China.
Jinyuan Xiao *Institute of Medical Information Engineering, Gannan Medical University, Ganzhou, 341000, China.
Chao ChenDepartment of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Min LiDepartment of Pathology, Peking University Third Hospital, Beijing, 100191, China.
Changjian YanThe Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China.
Xiaoni LiuDepartment of Respiratory Medicine, First Affiliated Hospital Gannan Medical University, Longnan Branch Hospital of the First Affiliated Hospital of Gannan Medical University, Clinical Medical College of Gannan Medical University, Ganzhou, 341000, China.
Xiaoyu HaoDepartment of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Yuqi ZhangDepartment of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Wenxin QiDepartment of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Yan LiuDepartment of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Jing WangDepartment of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Mingxia ZhuDepartment of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Ping YangDepartment of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China.
Xiaoliang YuanDepartment of Respiratory Medicine, First Affiliated Hospital Gannan Medical University, Longnan Branch Hospital of the First Affiliated Hospital of Gannan Medical University, Clinical Medical College of Gannan Medical University, Ganzhou, 341000, China.
Zining YuDepartment of Clinical Laboratory, Shangrao Municipal Hospital, Jiangxi, 334000, China.
Shixin WuDepartment of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China. wushixin7001@163.com.
Fang BaoDepartment of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China. baofang@bjmu.edu.cn.
Weilong ZhangDepartment of Hematology and Lymphoma Research Center, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, China. zhangwlpuh@126.com.

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-NCJH202201-0049National Natural Science Foundation of China 81800195Peking University Third Hospital BYSYZD2019026
6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive form of non-Hodgkin lymphoma. B symptoms, including fever, night sweats and weight loss, are often overlooked but carry prognostic significance. The primary site of DLBCL also plays a crucial role in diagnosis and treatment decisions, and our study aims to explore the relationship among primary sites of DLBCL, the presence of B symptoms and patients' survival. 15,267 patients' data were analyzed in our study to investigate the potential relevance among B symptoms, primary sites and patients' survival. We assessed the influence of primary site and B symptoms on survival with the use of Survival package and Kaplan-Meier survival analysis. Age, race and Ann-Arbor stage were significantly associated with the presence of B symptoms. The incidence rate of B symptoms varied across primary sites, bone marrow had the highest probability (43.75%), while the genital system had the lowest rate (13.58%). B symptoms were siginificant prognostic indicators among nodal DLBCL patients especially those involved lymph nodes of multiple regions, as well as patients with lymphoma originating from bone marrow, glands and respiration. Survival analysis revealed that bone marrow, genital organs, lymph nodes of multiple regions and head and neck are linked to poorer survival outcomes, which happen to be either the highest or lowest B symptom incidence sites. These findings highlight the prognostic importance of both primary tumor site and B symptom status in DLBCL patients.

Indexed as

Lymphoma, Large B-Cell, DiffuseAdolescentAdultAgedAged, 80 and overFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPrognosisSurvival RateYoung AdultB symptomsDLBCLExtranodal primary siteNodal primary sitePrognosis

Identifiers

PMID41071290
PMCPMC12672776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.